[This corrects the article on p. 75 in vol. 8, PMID: 28228756.].
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5388687 | PMC |
| http://dx.doi.org/10.3389/fimmu.2017.00381 | DOI Listing |
Publication Analysis
Top Keywords
corrigendum agonistic
4
agonistic anti-pdgf
4
anti-pdgf receptor
4
receptor autoantibodies
4
autoantibodies patients
4
patients systemic
4
systemic sclerosis
4
sclerosis impact
4
impact human
4
human pulmonary
4
Similar Publications
Corrigendum to "Retrospective review of seven patients with obesity simultaneously treated with a combination of a glucagon-like peptide-1 receptor agonist and a meal replacement product" [Obesity Pillars 12C (2024) 100138].
Obes Pillars
December 2024
Nestlé Health Science, Vevey, Switzerland.
[This corrects the article DOI: 10.1016/j.obpill.
View Article and Find Full Text PDFCorrigendum to "Tumor microenvironment immunomodulation by nanoformulated TLR 7/8 agonist and PI3k delta inhibitor enhances therapeutic benefits of radiotherapy" [Biomaterials 312 (2025) 122750.
Biomaterials
March 2025
Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA; Department of Medicine, University of North Carolina School of Medicine, Chapel Hill, NC, USA; Department of Microbiology and Immunology, University of North Carolina, Chapel Hill, NC, USA. Electronic address:
Corrigendum to "Results from three phase 1 trials of NNC9204-1177, a glucagon/GLP-1 receptor co-agonist: effects on weight loss and safety in adults with overweight or obesity" [Mol Metab 78 (2023) 101801].
Mol Metab
November 2024
Novo Nordisk A/S, Søborg, Denmark.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!